NO20064012L - Kjemisk prosess - Google Patents

Kjemisk prosess

Info

Publication number
NO20064012L
NO20064012L NO20064012A NO20064012A NO20064012L NO 20064012 L NO20064012 L NO 20064012L NO 20064012 A NO20064012 A NO 20064012A NO 20064012 A NO20064012 A NO 20064012A NO 20064012 L NO20064012 L NO 20064012L
Authority
NO
Norway
Prior art keywords
chemical process
formulas
compounds
preparation
chemical
Prior art date
Application number
NO20064012A
Other languages
English (en)
Inventor
John Roger Butlin
Philip John Hogan
Margaret Anne Butlin
Andreas Meudt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20064012L publication Critical patent/NO20064012L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Fremgangsmåte for fremstilling av forbindelser med formel I og IV er beskrevet.
NO20064012A 2004-02-20 2006-09-06 Kjemisk prosess NO20064012L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process
PCT/GB2005/000567 WO2005080403A2 (en) 2004-02-20 2005-02-17 Chemical process

Publications (1)

Publication Number Publication Date
NO20064012L true NO20064012L (no) 2006-11-06

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064012A NO20064012L (no) 2004-02-20 2006-09-06 Kjemisk prosess

Country Status (31)

Country Link
US (2) US7626020B2 (no)
EP (3) EP1718655A2 (no)
JP (2) JP2007523906A (no)
KR (2) KR20120036998A (no)
CN (1) CN1922193B (no)
AR (1) AR047810A1 (no)
AT (1) ATE535532T1 (no)
AU (1) AU2005214138B2 (no)
BR (1) BRPI0507847A (no)
CA (1) CA2555554A1 (no)
CL (1) CL2011003138A1 (no)
CY (1) CY1112555T1 (no)
DK (1) DK2135873T3 (no)
ES (1) ES2375201T3 (no)
GB (1) GB0403744D0 (no)
HR (1) HRP20120031T1 (no)
IL (2) IL177505A (no)
MY (1) MY142268A (no)
NO (1) NO20064012L (no)
PL (1) PL2135873T3 (no)
PT (1) PT2135873E (no)
RS (1) RS52300B (no)
RU (1) RU2386636C2 (no)
SA (1) SA05260017B1 (no)
SG (1) SG153856A1 (no)
SI (1) SI2135873T1 (no)
TW (1) TWI347947B (no)
UA (1) UA83418C2 (no)
UY (1) UY28754A1 (no)
WO (1) WO2005080403A2 (no)
ZA (1) ZA200606579B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2079734A1 (en) * 2006-10-25 2009-07-22 NeuroSearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
AU2009233711B2 (en) * 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
EP3913068B1 (en) 2015-10-12 2023-08-02 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (no) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (no) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO1999048530A1 (en) 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
NZ508154A (en) 1998-04-29 2003-07-25 Osi Pharm Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE60032517T2 (de) 2000-02-16 2007-10-04 Astellas Pharma Inc. Heilmittel gegen durch endothelin verursachte erkrankungen
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
IL158071A0 (en) 2001-04-11 2004-03-28 Abbott Lab Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003013518A1 (en) * 2001-08-03 2003-02-20 Smithkline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
WO2003015820A1 (en) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
DK1761515T3 (da) 2003-12-20 2009-02-16 Merck Patent Gmbh 2-(hetero-)aryl-substituerede tetrahydroquinolinderivater
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
RS52300B (sr) 2012-12-31
AU2005214138B2 (en) 2009-02-12
IL177505A (en) 2010-12-30
US20100094010A1 (en) 2010-04-15
CN1922193B (zh) 2012-12-26
RU2006133455A (ru) 2008-03-27
TW200538451A (en) 2005-12-01
EP2135873A2 (en) 2009-12-23
EP2135873B1 (en) 2011-11-30
TWI347947B (en) 2011-09-01
CL2011003138A1 (es) 2012-06-22
JP2007523906A (ja) 2007-08-23
DK2135873T3 (da) 2012-02-13
BRPI0507847A (pt) 2007-07-10
HRP20120031T1 (hr) 2012-02-29
EP2135873A3 (en) 2010-03-24
AU2005214138A1 (en) 2005-09-01
JP2012031174A (ja) 2012-02-16
US7626020B2 (en) 2009-12-01
AR047810A1 (es) 2006-02-22
US20080161565A1 (en) 2008-07-03
PT2135873E (pt) 2012-01-16
MY142268A (en) 2010-11-15
ES2375201T3 (es) 2012-02-27
UA83418C2 (uk) 2008-07-10
ZA200606579B (en) 2008-01-30
KR20120036998A (ko) 2012-04-18
PL2135873T3 (pl) 2012-03-30
IL177505A0 (en) 2006-12-10
EP2325189A3 (en) 2011-10-26
RU2386636C2 (ru) 2010-04-20
SG153856A1 (en) 2009-07-29
KR101196111B1 (ko) 2012-10-30
CY1112555T1 (el) 2016-02-10
WO2005080403A2 (en) 2005-09-01
UY28754A1 (es) 2005-09-30
CA2555554A1 (en) 2005-09-01
CN1922193A (zh) 2007-02-28
SA05260017B1 (ar) 2008-07-14
EP2325189A2 (en) 2011-05-25
KR20060129483A (ko) 2006-12-15
EP1718655A2 (en) 2006-11-08
IL194709A (en) 2010-12-30
GB0403744D0 (en) 2004-03-24
SI2135873T1 (sl) 2012-03-30
WO2005080403A3 (en) 2005-11-24
ATE535532T1 (de) 2011-12-15
HK1139689A1 (en) 2010-09-24

Similar Documents

Publication Publication Date Title
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20066055L (no) Pyridinderivater
DE602004007693D1 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
NO20050065L (no) Kjemiske forbindelser
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
NO20070782L (no) Tetrapeptidanaloger.
NO20060044L (no) Fremgangsmate for fremstilling av substituerte 3-aryl-butyl-aminforbindelser
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
TW200716543A (en) Chemical compounds VII
NO20085317L (no) Imidazoazepinonforbindelser
MXPA05011962A (es) Oxiarenos substituidos.
HRP20050359B1 (hr) Novi postupak za industrijsku sintezu stroncij renalata i njegovih hidrata
NO20055741D0 (no) Nye kjemiske forbindelser
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
NO20084177L (no) Substituerte Imidazo[2,1-B]thiazolforbindelser og deres anvendelse for produksjon av legemidler
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20073276L (no) Metode for fremstilling av aminoetoksybenzylalkoholer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application